Published in Ann Intern Med on November 21, 2006
Development of a large-scale de-identified DNA biobank to enable personalized medicine. Clin Pharmacol Ther (2008) 11.67
Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. J Clin Oncol (2009) 2.20
The pharmacogenetics research network: from SNP discovery to clinical drug response. Clin Pharmacol Ther (2007) 2.18
Genome-wide association studies in pharmacogenomics. Nat Rev Genet (2010) 2.14
Nicotine dependence pharmacogenetics: role of genetic variation in nicotine-metabolizing enzymes. J Neurogenet (2009) 2.07
Development and implementation of a pharmacist-managed clinical pharmacogenetics service. Am J Health Syst Pharm (2011) 1.85
Genetics of P450 oxidoreductase: sequence variation in 842 individuals of four ethnicities and activities of 15 missense mutations. Proc Natl Acad Sci U S A (2008) 1.47
Ethnic differences in cardiovascular drug response: potential contribution of pharmacogenetics. Circulation (2008) 1.44
From human genetics and genomics to pharmacogenetics and pharmacogenomics: past lessons, future directions. Drug Metab Rev (2008) 1.35
Genome-wide association studies in pharmacogenomics: successes and lessons. Pharmacogenet Genomics (2013) 1.30
Update on the evaluation of a new drug for effects on cardiac repolarization in humans: issues in early drug development. Br J Pharmacol (2009) 1.25
Integrating Epigenomics into Pharmacogenomic Studies. Pharmgenomics Pers Med (2008) 1.18
Assessing personalized medicines in Australia: a national framework for reviewing codependent technologies. Med Decis Making (2012) 1.15
Identifying the genotype behind the phenotype: a role model found in VKORC1 and its association with warfarin dosing. Pharmacogenomics (2007) 1.12
Genetic mechanisms of atrial fibrillation: impact on response to treatment. Nat Rev Cardiol (2013) 1.11
Human betaine-homocysteine methyltransferase (BHMT) and BHMT2: common gene sequence variation and functional characterization. Mol Genet Metab (2008) 1.05
Novel rare variants in congenital cardiac arrhythmia genes are frequent in drug-induced torsades de pointes. Pharmacogenomics J (2012) 1.00
Prospects for clinical cancer metabolomics using stable isotope tracers. Exp Mol Pathol (2009) 1.00
Integrating pharmacogenetic information and clinical decision support into the electronic health record. J Am Med Inform Assoc (2013) 0.98
Genetic variations in human glutathione transferase enzymes: significance for pharmacology and toxicology. Hum Genomics Proteomics (2010) 0.96
Nicotinic acetylcholine receptor beta2 subunit (CHRNB2) gene and short-term ability to quit smoking in response to nicotine patch. Cancer Epidemiol Biomarkers Prev (2009) 0.96
Sulfonylurea pharmacogenomics in Type 2 diabetes: the influence of drug target and diabetes risk polymorphisms. Expert Rev Cardiovasc Ther (2010) 0.95
Pharmacogenomics of CYP3A: considerations for HIV treatment. Pharmacogenomics (2009) 0.93
Differential impact of race and risk factors on incidence of atrial fibrillation. Am Heart J (2011) 0.91
Cardiac Arrhythmia: In vivo screening in the zebrafish to overcome complexity in drug discovery. Expert Opin Drug Discov (2010) 0.89
Genome-wide discovery of drug-dependent human liver regulatory elements. PLoS Genet (2014) 0.89
A multifaceted prospective memory intervention to improve medication adherence: design of a randomized control trial. Contemp Clin Trials (2012) 0.87
Cell-based Models for Discovery of Pharmacogenomic Markers of Anticancer Agent Toxicity. Trends Cancer Res (2008) 0.87
Cost-effectiveness of pharmacogenetic testing to tailor smoking-cessation treatment. Pharmacogenomics J (2008) 0.87
Natriuretic peptide receptor-3 gene (NPR3): nonsynonymous polymorphism results in significant reduction in protein expression because of accelerated degradation. Circ Cardiovasc Genet (2013) 0.86
Ranking gene-drug relationships in biomedical literature using Latent Dirichlet Allocation. Pac Symp Biocomput (2012) 0.86
Genomic medicine, precision medicine, personalized medicine: what's in a name? Clin Pharmacol Ther (2013) 0.84
Pharmacogenetics: implementing personalized medicine. Clin Cases Miner Bone Metab (2009) 0.83
Copy number variation and cytidine analogue cytotoxicity: a genome-wide association approach. BMC Genomics (2010) 0.83
Pharmacogenetics of etanercept in rheumatoid arthritis. Pharmacogenomics (2008) 0.82
Ethical concerns related to developing pharmacogenomic treatment strategies for addiction. Addict Sci Clin Pract (2011) 0.82
Exploring Willingness to Participate in Clinical Trials by Ethnicity. J Racial Ethn Health Disparities (2016) 0.81
From evidence based medicine to mechanism based medicine. Reviewing the role of pharmacogenetics. Int J Clin Pharm (2010) 0.80
The role of pharmacogenetics in nonmalignant gastrointestinal diseases. Nat Rev Gastroenterol Hepatol (2012) 0.79
Responding to the challenge of clinically relevant osteopathic research: efficacy and beyond. Int J Osteopath Med (2007) 0.79
Utility of Pretreatment Bilirubin Level and UGT1A1 Polymorphisms in Multivariate Predictive Models of Neutropenia Associated with Irinotecan Treatment in Previously Untreated Patients with Colorectal Cancer. Arch Drug Inf (2008) 0.79
Determining molecular predictors of adverse drug reactions with causality analysis based on structure learning. J Am Med Inform Assoc (2013) 0.78
Genetic polymorphisms of VIP variants in the Tajik ethnic group of northwest China. BMC Genet (2014) 0.77
Personalized medicine in cardiovascular diseases. Korean Circ J (2012) 0.76
Personalized medicine: identifying the appropriate patient through biomarkers in oncology. P T (2011) 0.76
Do Estrogen Receptor beta Polymorphisms Play A Role in the Pharmacogenetics of Estrogen Signaling? Curr Pharmacogenomics Person Med (2008) 0.75
Genetic Polymorphisms Analysis of Pharmacogenomic VIP Variants in Miao Ethnic Group of Southwest China. Med Sci Monit (2015) 0.75
Gene Co-Expression Analysis Predicts Genetic Variants Associated with Drug Responsiveness in Lung Cancer. AMIA Jt Summits Transl Sci Proc (2016) 0.75
The Potential of Pharmacogenomics to Advance Kidney Disease Treatment. Clin J Am Soc Nephrol (2017) 0.75
The Routine Clinical use of Pharmacogenetic Tests: What it Will Require? Pharm Res (2017) 0.75
A haplotype map of the human genome. Nature (2005) 105.70
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med (2004) 71.08
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (2004) 61.56
Complement factor H polymorphism in age-related macular degeneration. Science (2005) 31.10
Whole-genome patterns of common DNA variation in three human populations. Science (2005) 21.22
Complement factor H variant increases the risk of age-related macular degeneration. Science (2005) 17.95
Complement factor H polymorphism and age-related macular degeneration. Science (2005) 17.79
A comprehensive review of genetic association studies. Genet Med (2002) 16.75
Replication validity of genetic association studies. Nat Genet (2001) 16.30
Blocks of limited haplotype diversity revealed by high-resolution scanning of human chromosome 21. Science (2001) 15.54
Drug-induced prolongation of the QT interval. N Engl J Med (2004) 10.96
Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc Natl Acad Sci U S A (2000) 10.27
Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med (2005) 8.77
Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. N Engl J Med (2004) 8.62
Pharmacogenomics: translating functional genomics into rational therapeutics. Science (1999) 8.25
Genetic control of isoniazid metabolism in man. Br Med J (1960) 7.86
Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet (1999) 7.39
Pharmacogenomics--drug disposition, drug targets, and side effects. N Engl J Med (2003) 7.23
Drug-induced hepatotoxicity. N Engl J Med (2003) 7.11
Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature (2004) 5.95
Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A (2000) 5.89
Inheritance and drug response. N Engl J Med (2003) 5.78
Natural variation in human membrane transporter genes reveals evolutionary and functional constraints. Proc Natl Acad Sci U S A (2003) 5.77
The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat Genet (2004) 5.31
Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol (2004) 5.06
Parental atrial fibrillation as a risk factor for atrial fibrillation in offspring. JAMA (2004) 4.85
Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA (2004) 4.47
Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst (1999) 3.58
Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res (2000) 3.32
Genetic control of drug levels in man: antipyrine. Science (1968) 3.03
Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes. Circulation (2002) 2.98
Translation of pharmacogenomics and pharmacogenetics: a regulatory perspective. Nat Rev Drug Discov (2004) 2.96
Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther (2004) 2.81
Genetic control of drug levels in man: phenylbutazone. Science (1968) 2.72
Drug reactions enzymes, and biochemical genetics. J Am Med Assoc (1957) 2.67
Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient. Lancet (1993) 2.66
Genetic control of dicumarol levels in man. J Clin Invest (1968) 2.45
A common polymorphism associated with antibiotic-induced cardiac arrhythmia. Proc Natl Acad Sci U S A (2000) 2.26
Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia. J Pediatr (1991) 2.24
Mathematics is biology's next microscope, only better; biology is mathematics' next physics, only better. PLoS Biol (2004) 2.24
Corticosteroid pharmacogenetics: association of sequence variants in CRHR1 with improved lung function in asthmatics treated with inhaled corticosteroids. Hum Mol Genet (2004) 2.14
Permanent neonatal diabetes due to mutations in KCNJ11 encoding Kir6.2: patient characteristics and initial response to sulfonylurea therapy. Diabetes (2004) 2.10
Effects of a 5-lipoxygenase-activating protein inhibitor on biomarkers associated with risk of myocardial infarction: a randomized trial. JAMA (2005) 1.94
Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis. Hepatology (2003) 1.92
Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. J Clin Oncol (2001) 1.82
Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia. JAMA (2005) 1.74
Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology (2002) 1.64
Pharmacogenetics - five decades of therapeutic lessons from genetic diversity. Nat Rev Genet (2004) 1.59
Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Ann Intern Med (1998) 1.51
Effect of acetylator phenotype on the rate at which procainamide induces antinuclear antibodies and the lupus syndrome. N Engl J Med (1978) 1.37
Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. J Pharmacol Exp Ther (1995) 1.21
Role of organic cation transporters in drug absorption and elimination. Annu Rev Pharmacol Toxicol (1998) 1.20
Genetically variable metabolism of antidepressants and neuroleptic drugs in man. Pharmacogenetics (1993) 1.16
Pharmacogenetic aspects of drug-induced torsade de pointes: potential tool for improving clinical drug development and prescribing. Drug Saf (2004) 1.13
Pharmacogenetics and drug development: the path to safer and more effective drugs. Nat Rev Genet (2004) 1.11
Impact of ethnic origin and quinidine coadministration on codeine's disposition and pharmacodynamic effects. J Pharmacol Exp Ther (1999) 1.09
The use of pharmacokinetic and pharmacodynamic data in the assessment of drug safety in early drug development. Br J Clin Pharmacol (2004) 0.96
From bedside to bench to bedside to clinical practice: an odyssey with irinotecan. Clin Cancer Res (2006) 0.94
Sudden cardiac death, genes, and arrhythmogenesis: consideration of new population and mechanistic approaches from a National Heart, Lung, and Blood Institute workshop, Part II. Circulation (2001) 0.93
Human cardiac potassium channel DNA polymorphism modulates access to drug-binding site and causes drug resistance. J Clin Invest (2005) 0.93
Pharmacogenomic data: FDA voluntary and required submission guidance. Pharmacogenomics (2004) 0.92
Transporters and xenobiotic disposition. Toxicology (2002) 0.92
Asthma steroid pharmacogenetics: a study strategy to identify replicated treatment responses. Proc Am Thorac Soc (2004) 0.92
Paternal history of asthma and airway responsiveness in children with asthma. Am J Respir Crit Care Med (2005) 0.89
Evaluation of inhibitory drug interactions during drug development: genetic polymorphisms must be considered. Clin Pharmacol Ther (2005) 0.89
Proarrhythmia as a pharmacogenomic entity: a critical review and formulation of a unifying hypothesis. Cardiovasc Res (2005) 0.87
Pharmacogenomics. Cancer sharpshooters rely on DNA tests for a better aim. Science (2004) 0.85
The need for education in pharmacogenomics: a regulatory perspective. Pharmacogenomics J (2005) 0.85
Pharmacogenetics: ethical problems and solutions. Nat Rev Genet (2004) 0.84
3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) and genetic variability (single nucleotide polymorphisms) in a hepatic drug uptake transporter: what's it all about? Clin Pharmacol Ther (2004) 0.83
AmpliChip CYP450 test. Med Lett Drugs Ther (2005) 0.82
Long QT syndrome. Why does sex matter? Z Kardiol (2004) 0.81
Genetic nondiscrimination. Nat Genet (2005) 0.79
From genetics to cellular function using computational biology. Ann N Y Acad Sci (2004) 0.79
This month at the NIH: NIDDK forms hepatotoxicity clinical research network. Gastroenterology (2003) 0.77
Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation (2005) 43.74
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med (2010) 36.78
Biological, clinical and population relevance of 95 loci for blood lipids. Nature (2010) 28.21
Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat Genet (2008) 25.83
Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet (2010) 23.08
Hundreds of variants clustered in genomic loci and biological pathways affect human height. Nature (2010) 20.01
New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet (2010) 17.89
Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature (2007) 17.68
Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature (2011) 13.25
Personal omics profiling reveals dynamic molecular and medical phenotypes. Cell (2012) 12.32
From noncoding variant to phenotype via SORT1 at the 1p13 cholesterol locus. Nature (2010) 12.07
Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell (2002) 11.83
Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes. Nat Genet (2012) 11.09
Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med (2009) 10.54
Clinical assessment incorporating a personal genome. Lancet (2010) 10.18
BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature (2008) 10.12
Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med (2013) 9.44
Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med (2005) 8.77
Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst (2003) 8.66
Membrane transporters in drug development. Nat Rev Drug Discov (2010) 8.56
The chemical genomic portrait of yeast: uncovering a phenotype for all genes. Science (2008) 8.52
The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest (2006) 8.43
Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med (2009) 7.95
Meta-analysis identifies 13 new loci associated with waist-hip ratio and reveals sexual dimorphism in the genetic basis of fat distribution. Nat Genet (2010) 7.94
Acute lymphoblastic leukemia. N Engl J Med (2004) 7.83
TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. N Engl J Med (2006) 7.75
Common variants in the GDF5-UQCC region are associated with variation in human height. Nat Genet (2008) 7.31
The incidentalome: a threat to genomic medicine. JAMA (2006) 7.24
Pharmacogenomics--drug disposition, drug targets, and side effects. N Engl J Med (2003) 7.23
Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans. J Clin Invest (2009) 7.09
A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med (2013) 7.09
Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol (2005) 6.90
Population analysis of large copy number variants and hotspots of human genetic disease. Am J Hum Genet (2009) 6.79
Ethical and practical guidelines for reporting genetic research results to study participants: updated guidelines from a National Heart, Lung, and Blood Institute working group. Circ Cardiovasc Genet (2010) 6.74
Metabolism and disposition kinetics of nicotine. Pharmacol Rev (2005) 6.66
Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge. Nat Genet (2010) 6.66
Genetics. Genomic research and human subject privacy. Science (2004) 6.56
PharmGKB: the Pharmacogenetics Knowledge Base. Nucleic Acids Res (2002) 6.40
A Bayesian framework for combining heterogeneous data sources for gene function prediction (in Saccharomyces cerevisiae). Proc Natl Acad Sci U S A (2003) 6.19
Unique lipoprotein phenotype and genotype associated with exceptional longevity. JAMA (2003) 6.17
CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst (2005) 5.92
Natural variation in human membrane transporter genes reveals evolutionary and functional constraints. Proc Natl Acad Sci U S A (2003) 5.77
New loci associated with kidney function and chronic kidney disease. Nat Genet (2010) 5.58
Family-based tests for associating haplotypes with general phenotype data: application to asthma genetics. Genet Epidemiol (2004) 5.57
Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nat Genet (2012) 5.48
Genomic screening and replication using the same data set in family-based association testing. Nat Genet (2005) 5.44
Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med (2014) 5.37
Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer. J Natl Cancer Inst (2007) 5.13
Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer. J Clin Oncol (2004) 5.12
Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol (2004) 5.06
Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA (2009) 5.05
Cigarette smoking and infection. Arch Intern Med (2004) 5.04
Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. Lancet (2004) 5.01
Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia. Nat Genet (2011) 4.93
Implementing genomic medicine in the clinic: the future is here. Genet Med (2013) 4.89
Meta-analysis of prospective cohort studies evaluating the association of saturated fat with cardiovascular disease. Am J Clin Nutr (2010) 4.85
Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin Pharmacol Ther (2006) 4.81
Large-scale association analyses identify new loci influencing glycemic traits and provide insight into the underlying biological pathways. Nat Genet (2012) 4.73
PBAT: tools for family-based association studies. Am J Hum Genet (2004) 4.68
Serum vitamin D levels and markers of severity of childhood asthma in Costa Rica. Am J Respir Crit Care Med (2009) 4.64
Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial. Circulation (2010) 4.50
A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection. Science (2008) 4.50
Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest (2007) 4.47
A genome-wide approach accounting for body mass index identifies genetic variants influencing fasting glycemic traits and insulin resistance. Nat Genet (2012) 4.37
The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat (2006) 4.35
Genomics and drug response. N Engl J Med (2011) 4.35
CYP4F2 genetic variant alters required warfarin dose. Blood (2008) 4.23
Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital. Blood (2004) 4.21
Worldwide severity and control of asthma in children and adults: the global asthma insights and reality surveys. J Allergy Clin Immunol (2004) 4.17
Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N Engl J Med (2004) 4.16
Genome-wide trans-ancestry meta-analysis provides insight into the genetic architecture of type 2 diabetes susceptibility. Nat Genet (2014) 4.13
From pharmacogenomic knowledge acquisition to clinical applications: the PharmGKB as a clinical pharmacogenomic biomarker resource. Biomark Med (2011) 4.05
A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood (2008) 4.02
Knowledge acquisition, consistency checking and concurrency control for Gene Ontology (GO). Bioinformatics (2003) 3.97
Is vitamin D deficiency to blame for the asthma epidemic? J Allergy Clin Immunol (2007) 3.97
MMP12, lung function, and COPD in high-risk populations. N Engl J Med (2009) 3.96
Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet (2002) 3.95
SAFA: semi-automated footprinting analysis software for high-throughput quantification of nucleic acid footprinting experiments. RNA (2005) 3.95
Tumour heterogeneity in the clinic. Nature (2013) 3.92
Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet (2011) 3.92
Maternal intake of vitamin D during pregnancy and risk of recurrent wheeze in children at 3 y of age. Am J Clin Nutr (2007) 3.89
Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer. J Clin Oncol (2007) 3.86
UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. J Natl Cancer Inst (2007) 3.85
Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther (2004) 3.84
Genomewide association between GLCCI1 and response to glucocorticoid therapy in asthma. N Engl J Med (2011) 3.80
A genome-wide association study of pulmonary function measures in the Framingham Heart Study. PLoS Genet (2009) 3.78
Associating genes with gene ontology codes using a maximum entropy analysis of biomedical literature. Genome Res (2002) 3.77
Genetic loci influencing kidney function and chronic kidney disease. Nat Genet (2010) 3.75
Germline genomic variants associated with childhood acute lymphoblastic leukemia. Nat Genet (2009) 3.71
The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther (2003) 3.71
Meta-analysis of genome-wide association studies of asthma in ethnically diverse North American populations. Nat Genet (2011) 3.68
Guidelines on nicotine dose selection for in vivo research. Psychopharmacology (Berl) (2006) 3.68
Telomere length is paternally inherited and is associated with parental lifespan. Proc Natl Acad Sci U S A (2007) 3.67
Nonparametric methods for identifying differentially expressed genes in microarray data. Bioinformatics (2002) 3.65
Randomized Trial of Reduced-Nicotine Standards for Cigarettes. N Engl J Med (2015) 3.63